Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization

References

• Chen C, Wu N, Watson C. Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon. Clinicoecon Outcomes Res. 2018;10:723–730.
   Web of Science ®Google Scholar
• Reder AT, Oger JF, Kappos L, O’Connor P, Rametta M. Short-term and long-term safety and tolerability of interferon beta-1b in multiple sclerosis. Mult Scler Relat Disord. 2014;3(3):294–302. doi:10.1016/j.msard.2013.11.005
   PubMed Web of Science ®Google Scholar
• Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B, Wiendl H, Kieseier BC. Optimizing therapy early in multiple sclerosis: an evidence-based view. Mult Scler Relat Disord. 2015;4(5):460–469. doi:10.1016/j.msard.2015.07.007
   PubMed Web of Science ®Google Scholar
• Hamdy SM, Abdel-naseer M, Shalaby NM, et al. Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study. Neuropsychiatr Dis Treat. 2017;13:1895–1903. doi:10.2147/NDT
   Web of Science ®Google Scholar
• Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology. 1996;46(2):552–554. doi:10.1212/WNL.46.2.552
   Web of Science ®Google Scholar
• Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999;53(8):1622–1627. doi:10.1212/WNL.53.8.1622
   PubMed Web of Science ®Google Scholar
• The IFN-B Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655–661. doi:10.1212/WNL.43.4.655
   Web of Science ®Google Scholar
• The IFN-B Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277–1285. doi:10.1212/WNL.45.7.1277
   Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285–294.
   PubMed Web of Science ®Google Scholar
• Ebers GC. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498–1504. doi:10.1016/S0140-6736(98)03334-0
   PubMed Web of Science ®Google Scholar
• The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology. 1999;53(4):679–686. doi:10.1212/WNL.53.4.679
   Web of Science ®Google Scholar
• Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361(9357):545–552. doi:10.1016/S0140-6736(03)12512-3
   PubMed Web of Science ®Google Scholar
• La Mantia L, D’Amico D, Rigamonti A, Mascoli N, Bussone G, Milanese C. Interferon treatment may trigger primary headaches in multiple sclerosis patients. Mult Scler. 2006;12(4):476–480. doi:10.1191/1352458506ms1298oa
   Web of Science ®Google Scholar
• Khromov A, Segal M, Nissinoff J, Fast A. Migraines linked to interferon-beta treatment of multiple sclerosis. Am J Phys Med Rehabil. 2005;84(8):644–647. doi:10.1097/01.phm.0000171012.86932.10
   Web of Science ®Google Scholar
• Pollmann W, Erasmus LP, Feneberg W, Then Bergh F, Straube A. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology. 2002;59(4):636–639. doi:10.1212/WNL.59.4.636
   Web of Science ®Google Scholar
• Patti F, Nicoletti A, Pappalardo A, et al. Frequency and severity of headache is worsened by Interferon-beta therapy in patients with multiple sclerosis. Acta Neurol Scand. 2012;125(2):91–95. doi:10.1111/j.1600-0404.2011.01532.x
   PubMed Web of Science ®Google Scholar
• Olesen J, Bes A, Kunkel R, et al. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808. doi:10.1177/0333102413485658
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurology. 2011;69(2):292–302.
   PubMed Web of Science ®Google Scholar
• El-sherbiny NA, Shehata HS, Amer H, et al. Development and validation of an Arabic-language headache questionnaire for population-based surveys. J Pain Res. 2017;10:1289–1295. doi:10.2147/JPR.S137795
   Web of Science ®Google Scholar
• Bendtsen L, Birk S, Kasch H, et al. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012. J Headache Pain. 2012;13 Suppl(1):S1–S29. doi:10.1007/s10194-011-0402-9
   Web of Science ®Google Scholar
• Smith MY, Sabidó-Espin M, Trochanov A, et al. Post-marketing safety profile of subcutaneous interferon beta-1a given 3 times weekly: a retrospective administrative claims analysis. J Manag Care Spec Pharm. 2015;21(8):650–660. doi:10.18553/jmcp.2015.21.8.650
   Web of Science ®Google Scholar
• Sabidó-espin M, Munschauer R. Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study. BMC Neurol. 2017;17(1):57. doi:10.1186/s12883-017-0831-4
   Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology. 2002;59(10):1496–1506. doi:10.1212/01.WNL.0000034080.43681.DA
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Barbarash O, Casset-semanaz F, et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler. 2009;15(2):219–228. doi:10.1177/1352458508097299
   PubMed Web of Science ®Google Scholar
• Herndon RM, Rudick RA, Munschauer FE III, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler. 2005;11(4):409–419. doi:10.1191/1352458505ms1209oa
   Web of Science ®Google Scholar
• Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242–1249. doi:10.1212/01.wnl.0000237641.33768.8d
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903–914. doi:10.1016/S1474-4422(08)70200-X
   PubMed Web of Science ®Google Scholar
• O’connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889–897. doi:10.1016/S1474-4422(09)70226-1
   PubMed Web of Science ®Google Scholar
• Reder AT, Ebers GC, Traboulsee A, et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010;74(23):1877–1885. doi:10.1212/WNL.0b013e3181e240d0
   Web of Science ®Google Scholar
• Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, Phase 3, double-blind study. Lancet Neurol. 2014;13(7):657–665. doi:10.1016/S1474-4422(14)70068-7
   PubMed Web of Science ®Google Scholar
• Comi G, De Stefano N, Freedman MS, et al. Subcutaneous interferon beta-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the Phase III dosing frequency-blind multicentre REFLEXION study. J Neurol Neurosurg Psychiatry. 2017;88(4):285–294.
   PubMed Web of Science ®Google Scholar
• Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11(1):33–41. doi:10.1016/S1474-4422(11)70262-9
   PubMed Web of Science ®Google Scholar
• Hadjilambreva G, Mix E, Rolfs A, Muller J, Strauss U. Neuromodulation by a cytokine: interferon-beta differentially augments neocortical neuronal activity and excitability. J Neurophysiol. 2005;93(2):843–852. doi:10.1152/jn.01224.2003
   Web of Science ®Google Scholar
• Munno I, Marinaro M, Bassi A, Cassiano MA, Causarano V, Centonze V. Immunological aspects in migraine: increase of IL-10 plasma levels during attack. Headache. 2001;41(8):764–767. doi:10.1046/j.1526-4610.2001.01140.x
   PubMed Web of Science ®Google Scholar
• D’amico D, La Mantia L, Rigamonti A, et al. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia. 2004;24(11):980–984. doi:10.1111/j.1468-2982.2004.00790.x
   PubMed Web of Science ®Google Scholar
• Krusz JC. Tension-type headaches: what they are and how to treat them. Prim Care. 2004;31(2):293–311. doi:10.1016/j.pop.2004.02.004
   Web of Science ®Google Scholar
• Riley TL. Muscle-contraction headache. Neurol Clin. 1983;1(2):489–500. doi:10.1016/S0733-8619(18)31159-9
   Google Scholar
• Zebenholzer K, Lechner A, Broessner G, et al. Impact of depression and anxiety on burden and management of episodic and chronic headaches - a cross-sectional multicentre study in eight Austrian headache centres. J Headache Pain. 2016;17:15. doi:10.1186/s10194-016-0603-3
   PubMed Web of Science ®Google Scholar
• Zampieri MA, Tognola WA, Galego JC. Patients with chronic headache tend to have more psychological symptoms than those with sporadic episodes of pain. Arq Neuropsiquiatr. 2014;72(8):598–602. doi:10.1590/0004-282X20140084
   Web of Science ®Google Scholar
• Kister I, Caminero AB, Herbert J, Lipton RB. Tension-type headache and migraine in multiple sclerosis. Curr Pain Headache Rep. 2010;14(6):441–448. doi:10.1007/s11916-010-0143-5
   PubMed Web of Science ®Google Scholar